Intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration at twenty-four months: The pan-american collaborative retina study

Ophthalmology

Volumn 117, Issue 10, 2010, Pages

  Arevalo, J Fernando ^a   Snchez, Juan G ^b   Wu, Lihteh ^c   Berrocal, Maria H ^d   Alezzandrini, Arturo A ^e   Restrepo, Natalia ^b   Maia, Mauricio ^f   Farah, Michel E ^f   Brito, Miguel ^g   Daz Llopis, Manuel ^h   Rodrguez, Francisco J ⁱ   Reategui, Guillermo ^j   Iturralde Iraola, Juan ^g   Udaondo Mirete, Patricia ^h  

^a Retina and Vitreous Service   (Venezuela)

^b Instituto Nacional de Investigacin en Oftalmologa   (Colombia)

^c Instituto de Cirugia Ocular   (Costa Rica)

^d UNIVERSITY OF PUERTO RICO   (Puerto Rico)

^e UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^f FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^g Instituto Docente de Especialidades Oftalmolgicas   (Venezuela)

^h UNIVERSITY OF VALENCIA   (Spain)

ⁱ UNIVERSIDAD DEL ROSARIO   (Colombia)

^j Instituto Nacional de Oftalmología "Dr Francisco Contreras Campos"   (Peru)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CATARACT; DRUG DOSE COMPARISON; DRUG FATALITY; ENDOPHTHALMITIS; EYE EXAMINATION; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RETINA TEAR; RETROSPECTIVE STUDY; SIDE EFFECT; STROKE; SUBRETINAL NEOVASCULARIZATION; TREATMENT RESPONSE; UVEITIS; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; CHOROIDAL NEOVASCULARIZATION; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; INJECTION; MACULAR DEGENERATION; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; RETINA FOVEA; TIME; VERY ELDERLY; VITREOUS BODY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CHOROIDAL NEOVASCULARIZATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; FOVEA CENTRALIS; HUMANS; INJECTIONS; MACULAR DEGENERATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 84928585502     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2010.01.056     Document Type: Article

References (35)

1. D.J. D'Amico Diseases of the retina N Engl J Med 331 1994 95 105
2. Age-Related Eye Disease Study Research Group Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11 Arch Ophthalmol 121 2003 1621 1624
3. R. Klein, T. Peto, A. Bird, and M.R. Vannewkirk The epidemiology of age-related macular degeneration Am J Ophthalmol 137 2004 486 495
4. Eye Diseases Prevalence Research Group Causes and prevalence of visual impairment among adults in the United States Arch Ophthalmol 122 2004 477 485
5. Eye Diseases Prevalence Research Group Prevalence of age-related macular degeneration in the United States Arch Ophthalmol 122 2004 564 572
6. F.L. Ferris III, S.L. Fine, and L. Hyman Age-related macular degeneration and blindness due to neovascular maculopathy Arch Ophthalmol 102 1984 1640 1642
7. N. Ferrara Vascular endothelial growth factor: basic science and clinical progress Endocr Rev 25 2004 581 611 (Pubitemid 39099316)
8. J.W. Miller, A.P. Adamis, and D.T. Shima Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model Am J Pathol 145 1994 574 584
9. A.P. Adamis, D.T. Shima, and M.J. Tolentino Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate Arch Ophthalmol 114 1996 66 71
10. R. Amin, J.E. Puklin, and R.N. Frank Growth factor localization in choroidal neovascular membranes of age-related macular degeneration Invest Ophthalmol Vis Sci 35 1994 3178 3188
11. M. Kliffen, H.S. Sharma, and C.M. Mooy Increased expression of angiogenic growth factors in age-related maculopathy Br J Ophthalmol 81 1997 154 162
12. F.G. Holz, D. Pauleikhoff, R. Klein, and A.C. Bird Pathogenesis of lesions in late age-related macular disease Am J Ophthalmol 137 2004 504 510
13. M.G. Krzystolik, M.A. Afshari, and A.P. Adamis Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment Arch Ophthalmol 120 2002 338 346
14. E.S. Gragoudas, A.P. Adamis, E.T. Cunningham Jr VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group Pegaptanib for neovascular age-related macular degeneration N Engl J Med 351 2004 2805 2816
15. VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: an exploratory analysis Retina 25 2005 815 827
16. P. Van Wijngaarden, D.J. Coster, and K.A. Williams Inhibitors of ocular neovascularization: promises and potential problems JAMA 293 2005 1509 1513
17. N. Ferrara, K.J. Hillan, H.P. Gerber, and W. Novotny Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer Nat Rev Drug Discov 3 2004 391 400
18. R.F. Spaide, and Y.L. Fisher Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage Retina 26 2006 275 278
19. S. Michels, P.J. Rosenfeld, and C.A. Puliafito Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study Ophthalmology 112 2005 1035 1047
20. R.L. Avery, D.J. Pieramici, and M.D. Rabena Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration Ophthalmology 113 2006 363 372
21. D. Iturralde, R.F. Spaide, and C.B. Meyerle Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study Retina 26 2006 279 284
22. Z.F. Bashshur, A. Bazarbachi, and A. Schakal Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration Am J Ophthalmol 142 2006 1 9
23. F.B. Aggio, M.E. Farah, W.C. Silva, and G.B. Melo Intravitreal bevacizumab for exudative age-related macular degeneration after multiple treatments Graefes Arch Clin Exp Ophthalmol 245 2007 215 220
24. P. Yoganathan, V.A. Deramo, and J.C. Lai Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration Retina 26 2006 994 998
25. R.K. Maturi, L.A. Bleau, and D.L. Wilson Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment Retina 26 2006 270 274
26. J. Shahar, R.L. Avery, and G. Heilweil Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin) Retina 26 2006 262 269
27. R.P. Manzano, G.A. Peyman, P. Khan, and M. Kivilcim Testing intravitreal toxicity of bevacizumab (Avastin) Retina 26 2006 257 261
28. S.J. Bakri, T.A. Larson, and A.O. Edwards Intraocular inflammation following intravitreal injection of bevacizumab Graefes Arch Clin Exp Ophthalmol 246 2008 779 781
29. C.H. Meyer, S. Mennel, J.C. Schmidt, and P. Kroll Acute retinal pigment epithelial tear following intravitreal bevacizumab (Avastin) injection for occult choroidal revascularisation secondary to age related macular degeneration [letter] Br J Ophthalmol 90 2006 1207 1208
30. U.H. Spandau, and J.B. Jonas Retinal pigment epithelium tear after intravitreal bevacizumab for exudative age-related macular degeneration Am J Ophthalmol 142 2006 1068 1070
31. L. Wu, M.A. Martinez-Castellanos, H. Quiroz-Mercado Pan American Collaborative Retina Group (PACORES) Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES) Graefes Arch Clin Exp Ophthalmol 246 2008 81 87
32. P.J. Rosenfeld, A.A. Moshfeghi, and C.A. Puliafito Optical coherence tomography findings after intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration Ophthalmic Surg Lasers Imaging 36 2005 331 335
33. R.F. Spaide, K. Laud, and H.F. Fine Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration Retina 26 2006 383 390 (Pubitemid 44197628)
34. J.F. Arevalo, J. Fromow-Guerra, J.G. Sanchez Pan American Collaborative Retina Group (PACORES) Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up Retina 28 2008 1387 1394
35. M. Modarres, M. Naseripour, and K.G. Falavarjani Intravitreal injection of 2.5 mg versus 1.25 mg bevacizumab (Avastin) for treatment of CNV associated with AMD Retina 3 2009 319 324